Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: Results of 2 phase 1 studies

Blood

Volumn 112, Issue 6, 2008, Pages 2232-2241

  Davies, Jeff K ^a,b   Gribben, John G ^c   Brennan, Lisa L ^a   Yuk, Dongin ^a   Nadler, Lee M ^a,b   Guinan, Eva C ^a,d,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; BLOOD DONOR; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE FREE SURVIVAL; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MYCOSIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEPSIS; T LYMPHOCYTE; VIRUS INFECTION; VIRUS REACTIVATION; ADOLESCENT; BLOOD DISEASE; BONE MARROW DISEASE; CLONAL ANERGY; CYTOMEGALOVIRUS INFECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HISTOCOMPATIBILITY; IMMUNOLOGY; INFANT; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MIDDLE AGED; MORTALITY; PHASE 1 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE MARROW DISEASES; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CLONAL ANERGY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; ISOANTIGENS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TREATMENT OUTCOME;

EID: 55249127599     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143636     Document Type: Article

References (50)

1. SpitzerTR. Haploidentical stem cell transplantation: the always present but overlooked donor. Hematology (Am Soc Hematol Educ Program). 2005:390-395.
2. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants tor leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-1777.
3. Munn RK. Henslee-Downey PJ, Romond EH, et al. Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant. 1997;19:421-427.
4. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447-3454.
5. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood. 1989;73:1340-1350.
6. Horowitz MM, Gale RP, Sondel PM, et al. Graftversus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
7. Henslee PJ, Thompson JS, Romond EH. et al. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect. Transplant Proc. 1987;19:2701-2706.
8. Cavazzana-Calvo M, Fromont C, Le Deist F et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation. 1990;50:1-7.
9. Davies JK, Koh MB, Lowdell MW. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant. 2004;10:259-268.
10. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003;102:2292-2299.
11. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood. 2004;103: 1158-1165.
12. Mielke S, Rezvani K. Savani BN, et al. Reconstitution of foxp3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versushost disease (GVHD). Blood. 2007;110:1689-1697.
13. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;169:1042-1049.
14. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994;15:321-331.
15. Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996;87:4887-4893.
16. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340: 1704-1714.
17. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graftversus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97: 855-864.
18. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graftversus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989;4:247-254.
19. Karnofsky D, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:196
20. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987;60: 1651-1656.
21. Ohnishi M, Sakurai T, HeikeY, et al. Evaluation of cytomegalovirus- specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gammaenzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol. 2005;131: 472-479.
22. Kaplan E. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 457-481.
23. Klein J, Moeschberger ML. Survival analysis: techniques of censored and truncated data. New York: Springer-Verlag; 2003.
24. Powles R, Singhal S, Treleaven J. et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood. 1998;91:3481-3486.
25. Savani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13:1216-1223.
26. Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant. 2008;41:245-252.
27. Eyrich M, Lang P, Lal S, et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigendisparate haematopoietic stem cells from parental donors. Br J Haematol. 2001;114:422-432.
28. Amrolia PJ, Muccioli-Casadei G, Huls H, etal. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006; 108:1797-1808.
29. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007;25:690-697.
30. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232-1240.
31. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
32. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
33. Davies JK, Yuk D, Nadler LM, Guinan EC. T cells can be rendered hyporesponsive to alloantigen without loss of pathogen or tumor immunity. Transplantation. 2008 (in press).
34. Muller S, Schulz A, Reiss U, et al. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant. 1999;24:575-581.
35. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339:1186-1193.
36. Koenen HJ, Joosten I. Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood. 2000;95:3153-3161.
37. Schild H, Mavaddat N, Litzenberger C, et al. The nature of major histocompatibility complex recognition by gamma delta T cells. Cell. 1994;76:29-37.
38. Newell KA, He G, Guo Z, et al. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+T cells. J Immunol. 1999; 163:2358-2362.
39. Tian L, Guo W, Yuan Z, et al. Association of the CD134/GD134L costimulatory pathway with acute rejection of small bowel allograft. Transplantation. 2002;74:133-138.
40. Marks Dl, Khattry N, Cummins M, et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol. 2006;134: 196-201.
41. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion tor the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291-297.
42. Waller EK, Giver CR, Rosenthal H, et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis. 2004;33:233-237.
43. Walker I, Shehata N, Cantin G, et al. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis. 2004;33: 222-226.
44. Barge RM; Starrenburg CW, Falkenburg JH, et al. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant. 2006;37:1129-1134.
45. Saavedra S. Sanz GF. Jarque I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant. 2002;30:937-943.
46. TomonariA, Iseki T. Ooi J, et al. Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol. 2003;121:304-311.
47. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004; 10:186-194.
48. Anasetti C, Amos D, Beatty PG; et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
49. Eapen M, Rubinstein P, Zhang MJ. et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369:1947-1954.
50. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275.